Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12244MR)

This product GTTS-WQ12244MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12244MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11863MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ9202MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ13117MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ13807MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ22MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ6394MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ8089MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ15198MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW